Back to List/Filter


TRANSFORM-2

NCT04468984

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
Alfred Health (Haematology)
The Alfred, Commercial Road, Melbourne VIC, Australia
Recruiting
Primary Contact : Nola Kennedy, N.Kennedy@alfred.org.au , 03 9076 2217
Calvary Mater Newcastle Hospital (Haematology)
Edith St & Platt St, Waratah NSW 2298, Australia
Recruiting
Primary Contact : Michele Gambrill, michele.gambrill@calvarymater.org.au , 02 4014 4891
Royal Perth Hospital (Haematology)
Victoria Square, Perth WA 6000, Australia
Recruiting
Primary Contact : Aida Morynko, Aida.morynko@health.wa.gov.au , +618 92241343
Secondary Contact : Lisa Forsyth, lisa.forsyth@health.wa.gov.au , +618 9224 8478
St Vincents Hospital, Sydney (Haematology)
Darlinghurst, Sydney, NSW
Recruiting
Primary Contact : Louise Christopherson, louise.christophersen@svha.org.au , 02 9355 5702

2020-000557-27M20-178

Interventional

Treatment - Drugs

Phase 3

18

100

04/12/2020

N/A

Open

By Specialist and/or Surgeon Referral

Any or not stated

No

No

No
Haematology
Myeloproliferative Disorders
Myelofibrosis
N/A

20120092